Oculis
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the a...
Latest News
6 months ago · marketbeat.com
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision GoalsOculis NASDAQ: OCS said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug candidate in that indication.
6 months ago · globenewswire.com
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
6 months ago · globenewswire.com
Íslensk þýðing á fyrri tilkynningu; Oculis tilkynnir um helstu niðurstöður úr fasa 3 DIAMOND rannsóknunum á OCS-01 við sjónhimnubjúg af völdum sykursýkiZug, Sviss, May 29, 2026 (GLOBE NEWSWIRE) -- Aðalviðmiðið (e. primary endpoint) um breytingu á sjónskerpu frá upphafspunkti og fram að viku 52 náðist í hvorugri fasa 3 rannsókninni Önnur viðmið (e. secondary endpoint) um breytingu á þykkt sjónhimnunnar sýndi fram á verulega og varanlega minnkun með OCS-01 miðað við lyfleysu í báðum rannsóknunum Oculis mun beina þróunarstarfi og fjármagni að yfirstandandi PIONEER-skráningaráætluninni á Privosegtor við sjóntaugakvillum og PREDICT-1 skráningarrannsókninni á Licaminlimab við augnþurrki (e.
6 months ago · globenewswire.com
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular EdemaZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash runway into 2H 2029 Conference call today at 4:30 pm ET Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema (DME). The DIAMOND (DIAbetic Macular edema patients ON a Drop) program consisted of two Phase 3, double-masked, randomized, multi-center trials to evaluate the efficacy and safety of OCS-01 eye drops in patients with DME following 52 weeks of treatment.
6 months ago · globenewswire.com
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of DirectorsZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m. CEST, including the election of Gregory D. Perry to its Board of Directors.
6 months ago · zacks.com
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue EstimatesOculis Holding AG (OCS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.77 per share a year ago.
6 months ago · globenewswire.com
Oculis Reports Q1 2026 Financial Results and Provides Company UpdateZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, Pioneering a Genotype-Driven Path to Precision Medicine in Dry Eye Disease Privosegtor Regulatory Path Cleared via FDA SPA; PIONEER-1 Phase 3 Trial Advances with Ongoing Site Activation Cash, cash equivalents, and short-term investments of $277.6 million as of March 31, 2026, providing cash runway into 2H 2029 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the first quarter ended March 31, 2026, and provided an overview of the Company's progress. Riad Sherif, M.D.
6 months ago · globenewswire.com
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational TrialZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) regarding PIONEER-1, the first registrational trial within the PIONEER Program evaluating Privosegtor for the treatment of optic neuritis (ON). This formal FDA agreement confirms the design and planned analysis of the PIONEER-1 study are adequate to address the objectives necessary to support a future NDA submission, subject to a successful trial outcome and FDA review of the complete submission.
7 months ago · globenewswire.com
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual MeetingKey findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report topline results in June 2026 from DIAMOND Phase 3 registrational trials with OCS-01, which aims to be the first eye drop therapy for DME ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announces that the latest findings of the DME AWARE Delphi study were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. DME affects mainly a working-age population and is typically diagnosed at an average age of 52 years.1, 2 One year following diagnosis, 60% of patients are not treated2a while we know that delaying treatment is not beneficial for patients as it represents a missed opportunity to fully regain vision.
7 months ago · globenewswire.com
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it will be highlighting the transformative potential of its late-stage pipeline, recent development milestones achieved and key areas of unmet medical needs at the Eyecelerator and Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove OCS